Wolters Kluwer Health, The Altos Group Partner to Develop Sepsis Mortality Reduction Program

Wolters Kluwer Health, The Altos Group Partner to Develop Sepsis Mortality Reduction Program

<0> Wolters Kluwer Health | Clinical SolutionsCheri Palmer, 612-217-5253Vice President, Commercial Programs </0>

is a consulting firm that partners with healthcare institutions to implement change management programs that substantially improve patient outcomes. Headed by Julie A. Kliger, MPA, BSN, the firm’s methodology and services have proven particularly effective at impacting sepsis rates. In one case, which was recently by the Agency for Healthcare Research and Quality (AHRQ), a 54.5% reduction in average mortality rates was achieved within three years across nine California hospitals.

“Sepsis is the top preventable cause of death in hospitals. And while hospitals have been proactive in their efforts to reduce its devastating and often fatal consequences, sepsis rates remain unacceptably high because traditional approaches fail to address the human factors involved in early detection and proper treatment,” said Kliger. “By combining The Altos Group’s change management expertise with Wolters Kluwer Health’s advanced decision support technologies and superior clinical content, we are closing the gaps that have hampered hospitals’ efforts to intervene before sepsis becomes life-threatening.”

The sepsis mortality reduction program focuses on early detection and applying best practices to treating the septic patient. In addition to reducing overall patient mortality, costs and lengths of stay, the goal of the program is to identify and address the top healthcare-associated infections (HAI) that drive sepsis mortality. This will be accomplished through a three-pronged approach that couples mobile software with actionable content, driven by Wolters Kluwer Health’s trusted brands including , , , and , supplemented by change management consulting services.

“A sepsis crisis is gripping the U.S. healthcare system, claiming 215,000 lives and burdening the system with $16.7 billion in unnecessary healthcare expenditures. Software and clinical content alone are not enough to change that. Sepsis can only be eliminated if we also pay attention to workflow and human factors,” said Linda R. Peitzman, M.D., Chief Medical Officer, Wolters Kluwer Health Clinical Solutions. “The Altos Group brings to our program the guidance and expertise required to build appropriate teams, develop an infrastructure and framework for organizational improvement, and align key stakeholders across a facility. By integrating all three elements, we can affect the change necessary to reduce the needless loss of life to sepsis.”

Hospitals interested in being considered as a pilot site for the sepsis mortality reduction program should contact Andy Strunk, Innovation Lab Program Director, at (425) 214-0121 or .

Wolters Kluwer Health (Philadelphia, PA) is a leading global provider of information, business intelligence and point-of-care solutions for the healthcare industry. Serving more than 150 countries and territories worldwide, Wolters Kluwer Health’s customers include professionals, institutions and students in medicine, nursing, allied health and pharmacy. Major brands include traditional publishers of medical and drug reference tools, journals and textbooks, such as ; and electronic information providers, such as , , , , , , and .

is part of , a market-leading global information services company. Wolters Kluwer has 2011 annual revenues of €3.4 billion ($4.7 billion), employs approximately 19,000 people worldwide, and maintains operations in over 40 countries across Europe, North America, Asia Pacific, and Latin America.

Suggested Articles

J&J's talc woes deepened Friday after the FDA turned up "sub-trace" levels of asbestos one bottle of the company's baby powder,…

Another major drugmaker is recalling in the U.K. 10 batches of its Zantac generics because they contain a possible carcinogen.

With diagnosis rates on the rise, Pfizer's Vyndaqel franchise could collect $157 million in 2019 U.S. sales, well above consensus, SVB Leerink says.